Literature DB >> 33704747

Integrated Approach for the Diagnosis of Shiga Toxin-Producing Escherichia coli Infections in Humans.

Stefano Morabito1, Fabio Minelli1, Rosangela Tozzoli2.   

Abstract

Shiga toxin-producing Escherichia coli (STEC) are human pathogens causing severe diseases, such as hemorrhagic colitis and the hemolytic uremic syndrome. The prompt diagnosis of STEC infection is of primary importance to drive the most appropriate patient's management procedures. The methods to diagnose STEC infections include both direct isolation of the STEC from stool samples and the identification of indirect evidences based on molecular, phenotypic, and serological applications. Here, the procedures in use at the Italian Reference Laboratory for E. coli infections are described.

Entities:  

Keywords:  Anti-lipopolysaccharide antibodies; ELISA; Real time PCR; STEC isolation; Serology; Shiga toxin; Vero cell assay

Mesh:

Year:  2021        PMID: 33704747     DOI: 10.1007/978-1-0716-1339-9_1

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  15 in total

Review 1.  Shiga toxin-associated hemolytic uremic syndrome: advances in pathogenesis and therapeutics.

Authors:  Tania N Petruzziello-Pellegrini; Philip A Marsden
Journal:  Curr Opin Nephrol Hypertens       Date:  2012-07       Impact factor: 2.894

2.  Management of hemolytic uremic syndrome.

Authors:  Chantal Loirat; Jeffrey Saland; Martin Bitzan
Journal:  Presse Med       Date:  2012-01-27       Impact factor: 1.228

Review 3.  Shiga Toxin-Producing Escherichia coli Infection, Antibiotics, and Risk of Developing Hemolytic Uremic Syndrome: A Meta-analysis.

Authors:  Stephen B Freedman; Jianling Xie; Madisen S Neufeld; William L Hamilton; Lisa Hartling; Phillip I Tarr; Alberto Nettel-Aguirre; Anderson Chuck; Bonita Lee; David Johnson; Gillian Currie; James Talbot; Jason Jiang; Jim Dickinson; Jim Kellner; Judy MacDonald; Larry Svenson; Linda Chui; Marie Louie; Martin Lavoie; Mohamed Eltorki; Otto Vanderkooi; Raymond Tellier; Samina Ali; Steven Drews; Tim Graham; Xiao-Li Pang
Journal:  Clin Infect Dis       Date:  2016-02-24       Impact factor: 9.079

4.  Escherichia coli harboring Shiga toxin 2 gene variants: frequency and association with clinical symptoms.

Authors:  Alexander W Friedrich; Martina Bielaszewska; Wen-Lan Zhang; Matthias Pulz; Thorsten Kuczius; Andrea Ammon; Helge Karch
Journal:  J Infect Dis       Date:  2001-12-14       Impact factor: 5.226

Review 5.  Antibiotic treatment of verocytotoxin-producing Escherichia coli (VTEC) infection: a systematic review and a proposal.

Authors:  Morten Agger; Flemming Scheutz; Steen Villumsen; Kåre Mølbak; Andreas Munk Petersen
Journal:  J Antimicrob Chemother       Date:  2015-06-20       Impact factor: 5.790

Review 6.  Shiga toxin-induced haemolytic uraemic syndrome and the role of antibiotics: a global overview.

Authors:  Loukas Kakoullis; Eleni Papachristodoulou; Paraskevi Chra; George Panos
Journal:  J Infect       Date:  2019-05-28       Impact factor: 6.072

7.  Multicenter evaluation of a sequence-based protocol for subtyping Shiga toxins and standardizing Stx nomenclature.

Authors:  Flemming Scheutz; Louise D Teel; Lothar Beutin; Denis Piérard; Glenn Buvens; Helge Karch; Alexander Mellmann; Alfredo Caprioli; Rosangela Tozzoli; Stefano Morabito; Nancy A Strockbine; Angela R Melton-Celsa; Maria Sanchez; Søren Persson; Alison D O'Brien
Journal:  J Clin Microbiol       Date:  2012-07-03       Impact factor: 5.948

8.  Risk of hemolytic uremic syndrome after antibiotic treatment of Escherichia coli O157:H7 enteritis: a meta-analysis.

Authors:  Nasia Safdar; Adnan Said; Ronald E Gangnon; Dennis G Maki
Journal:  JAMA       Date:  2002-08-28       Impact factor: 56.272

Review 9.  Hemolytic uremic syndrome.

Authors:  Marina Noris; Giuseppe Remuzzi
Journal:  J Am Soc Nephrol       Date:  2005-02-23       Impact factor: 10.121

10.  Haemolytic uremic syndrome surveillance in children less than 15 years in Belgium, 2009-2015.

Authors:  S Jacquinet; K De Rauw; D Pierard; N Godefroid; L Collard; K Van Hoeck; M Sabbe
Journal:  Arch Public Health       Date:  2018-08-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.